Key terms
About BBIO
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BBIO news
May 02
8:35pm ET
Buy Rating Affirmed: BridgeBio Pharma’s Growth Trajectory Bolstered by Strong Pipeline and Strategic Initiatives
May 02
7:33am ET
BridgeBio reports Q1 EPS (20c), consensus (89c)
May 02
7:26am ET
BridgeBio launches BBOT with $200M of private external capital
May 02
3:23am ET
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), GE Healthcare Technologies Inc (GEHC) and Tenet Healthcare (THC)
May 02
2:22am ET
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Aurinia Pharmaceuticals (AUPH) and 908 Devices (MASS)
May 02
2:20am ET
Buy Rating Justified by BridgeBio Pharma’s Strategic Position and Promising Drug Candidates
May 01
5:07am ET
3 Best Stocks to Buy Now, 5/1/2024, According to Top Analysts
Apr 30
9:29am ET
Bank of America Securities Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
Apr 30
6:17am ET
Strong Buy Rating for BridgeBio Pharma Amid Positive HELIOS-B Study and Promising Infigratinib Developments
Apr 29
11:35pm ET
Maintaining Buy Rating on BridgeBio Pharma: Undervalued Potential of Acoramidis Amid Market Underperformance
Apr 08
5:46am ET
Buy Rating Affirmed for BridgeBio Pharma on Acoramidis’ Positive ATTR-CM Trial Outcomes
Mar 24
9:47pm ET
Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments
Mar 21
4:45am ET
BridgeBio assumed with an Outperform at Raymond James
Mar 20
7:32am ET
BridgeBio reports inducement grants under Nasdaq listing rule
Mar 20
6:10am ET
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Jazz Pharmaceuticals (JAZZ)
Mar 20
5:55am ET
BridgeBio price target raised to $45 from $35 at JPMorgan
Mar 19
7:34am ET
BridgeBio price target raised to $70 from $60 at Cantor Fitzgerald
Mar 18
10:55am ET
BridgeBio participates in a conference call with Cantor Fitzgerald
Mar 18
9:48am ET
BridgeBio participates in a conference call with Cantor Fitzgerald
Mar 06
11:20pm ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (PEPG), BridgeBio Pharma (BBIO) and Amedisys (AMED)
Mar 06
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Mar 06
6:22am ET
BridgeBio 8.6M share Secondary priced at $29.00
Mar 05
6:35am ET
BridgeBio price target lowered to $53 from $60 at Mizuho
Mar 05
5:12am ET
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Elevance Health (ELV)
Mar 05
5:01am ET
Analysts’ Top Healthcare Picks: Avidity Biosciences (RNA), Irhythm Technologies (IRTC)
Mar 04
7:06pm ET
Buy Rating Affirmed for BridgeBio Pharma Amidst Strategic Bayer Collaboration and Promising Financial Outlook
Mar 04
4:18pm ET
BridgeBio announces $250M common stock offering
Mar 04
2:25pm ET
Maintained Buy Rating for BridgeBio Pharma Amidst Strategic Partnerships and Market Growth Potential
Mar 04
5:18am ET
BridgeBio, Bayer announce European licensing agreement for acoramidis
Feb 29
6:26am ET
Optimistic Buy Rating for BridgeBio Pharma Amid Strong Market Position and Promising Treatment Pipeline
Feb 25
11:30pm ET
Buy Rating Affirmed for BridgeBio Pharma on Strong Clinical Progress and Strategic Financial Positioning
No recent press releases are available for BBIO
BBIO Financials
Key terms
Ad Feedback
BBIO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BBIO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
